

Page 1

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 6 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 8 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased
to 50,000
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and
functionality
NEWS 13 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 14 DEC 18 CA/CAplus patent kind codes updated
NEWS 15 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased
to 50,000
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 17 DEC 27 CA/CAplus enhanced with more pre-1907 records
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22 JAN 22 CA/CAplus updated with revised CAS roles
NEWS 23 JAN 22 CA/CAplus enhanced with patent applications from India
NEWS 24 JAN 29 PHAR reloaded with new search and display fields
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 26 FEB 13 CASREACT coverage to be extended
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

10520766a.trn

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:13:26 ON 20 FEB 2007

FILE 'REGISTRY' ENTERED AT 17:13:36 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6
DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10520766\Struc 2.str
```



chain nodes :

18 19 20 21 22 23 24 30

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26 27 28 29

chain bonds :

1-18 3-19 5-20 7-21 15-22 22-23 22-24 24-25 27-30

ring bonds :

1-2 1-16 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14

14-15 15-16 25-26 25-29 26-27 27-28 28-29

exact/norm bonds :

1-2 1-16 1-18 2-3 3-4 3-19 4-5 5-6 5-20 6-7 7-8 7-21 8-9 9-10 10-11

11-12 12-13 13-14 14-15 15-16 25-26 25-29 26-27 27-28 28-29

exact bonds :

15-22 22-23 22-24 24-25 27-30

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=> 11
SAMPLE SEARCH INITIATED 17:13:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE


100.0% PROCESSED 66 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 452 TO 1228
```

L2 42 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10520766\Struc 3.str



```
chain nodes :
18 19 20 21 22 23 24 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26 27 28 29
chain bonds :
1-18 3-19 5-20 7-21 15-22 15-31 22-23 22-24 24-25 27-30
ring bonds :
1-2 1-16 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
14-15 15-16 25-26 25-29 26-27 27-28 28-29
exact/norm bonds :
1-2 1-16 1-18 2-3 3-4 3-19 4-5 5-6 5-20 6-7 7-8 7-21 8-9 9-10 10-11
11-12 12-13 13-14 14-15 15-16 15-31 25-26 25-29 26-27 27-28 28-29
exact bonds :
15-22 22-23 22-24 24-25 27-30
```

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS 31:CLASS
10520766a.trn

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> l3
SAMPLE SEARCH INITIATED 17:14:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> l3 full
FULL SEARCH INITIATED 17:14:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1276 TO ITERATE

100.0% PROCESSED 1276 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L5 6 SEA SSS FUL L3

=> file medline caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'MEDLINE' ENTERED AT 17:14:48 ON 20 FEB 2007

FILE 'CAPLUS' ENTERED AT 17:14:48 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> l5
L6 5 L5

=> d ibib abs hitstr 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60497 CAPLUS

DOCUMENT NUMBER: 140:111193

TITLE: Novel macrocycles for the treatment of cancer

diseases

INVENTOR(S): Hoeffle, Gerhard

PATENT ASSIGNEE(S): Gesellschaft Fuer Biotechnologische Forschung GmbH (GBF), Germany

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------------|------------------|------------|
| WO 2004007493 | A1 | 20040122 | WO 2003-EP7663 | 20030715 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS: MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10232094 | A1 | 20040205 | DE 2002-10232094 | 20020715 |
| CA 2491422 | A1 | 20040122 | CA 2003-2491422 | 20030715 |
| AU 2003250957 | A1 | 20040202 | AU 2003-250957 | 20030715 |
| EP 1521750 | A1 | 20050413 | EP 2003-763869 | 20030715 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2005535669 | T | 20051124 | JP 2004-520646 | 20030715 |
| US 2006122241 | A1 | 20060608 | US 2005-520766 | 20050722 |
| PRIORITY APPLN. INFO.: | | | DE 2002-10232094 | A 20020715 |
| | | WO 2003-EP7663 | W 20030715 | |

OTHER SOURCE(S): MARPAT 140:111193

GI

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB: The invention relates to novel macrocycles I [R1 = Cl-6-alkyl, C2-6-alkynyl, C2-6-alkenyl; R2 = H, Cl-6-alkyl; XY = CH:CH, oxirane; R3 = halogen, Cl-6-alkyl, C2-6-alkenyl, Cl-6-heteroaryl, CF3; R4 = bicycloaryl, bicycloheteroaryl, CR5:CHR6; R5 = H, Me; R6 = substituted aryl, heteroaryl], or a pharmaceutically acceptable, salt, solvate or hydrate thereof, and to the use thereof in the treatment of cancer diseases.

IT 647835-14-1 647835-16-3


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 647835-14-1 CAPLUS

CN: Acycliclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-16-(trifluoromethyl)-(45,7R,8S,9S,13S,16S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 647835-16-3 CAPLUS

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 4,17-Dioxabicyclo[4.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-

8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-3-(trifluoromethyl)-, (1S,3S,7S,10R,11S,12S,16R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60492 CAPLUS

DOCUMENT NUMBER: 140:111192

TITLE: Preparation of epothilone derivatives for therapeutic use in the treatment of cancer and other cell proliferation diseases

INVENTOR(S): Hoeffle, Gerhard

PATENT ASSIGNEE(S): Gesellschaft Fuer Biotechnologische Forschung mbH (GBF), Germany

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2004007476 | A1 | 20040122 | WO 2003-EP6066 | 20030610 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS: MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10232094 | A1 | 20040205 | DE 2002-10232094 | 20020715 |
| CA 24934609 | A1 | 20040202 | CA 2003-246409 | 20030610 |
| AU 2003246409 | A1 | 20040202 | AU 2003-246409 | 20030610 |
| PRIORITY APPLN. INFO.: | | | DE 2002-10232094 | A 20020715 |
| | | | WO 2003-EP6066 | W 20030610 |

GI



I


AB: This invention relates to the preparation of epothilone derivs., such I [X = CO, SO; X = CO, if R3 = H; Y-Z = C(=CH2)-2,3-oxirandiyil(epoxide) ring; R1 = alkyl, alkenyl; R2 = H, alkyl; R3= H, alkyl, alkenyl; R4 = bicycloaryl, bicycloheteroaryl, -(CR5)CH-R6; R5 = H, Me; R6 = aryl, heteroaryl], and their use as antitumor and cytotoxic therapeutic agents. Detailed synthesis and biol. testing data was not presented.

IT 219989-77-2P, 15-Methyllepothilone B

RL: PHN (Preparation, unclassified); THU (Therapeutic use); BIOL

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Biological study); PREP (Preparation); USES (Uses);
 (prep. of epothilone derivs. for therapeutic use in the treatment of
 cancer and other cell proliferation diseases)
 RN 219989-77-2 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-
 3,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-
 thiazolyl)ethenyl]-. (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESION NUMBER: 2002:716079 CAPLUS
 DOCUMENT NUMBER: 137:242152
 TITLE: Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
 INVENTOR(S): Lee, Francis Y. F.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl. 125 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| WO 2002072085 | A1 | 20020919 | WO 2002-US6746 | 20020305 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RU: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2440555 | A1 | 20020919 | CA 2002-2440555 | 20020305 |
| US 2003073677 | A1 | 20030417 | US 2002-91061 | 20020305 |
| EE 200300440 | A | 20031215 | EE 2003-440 | 20020305 |
| EP 1383490 | A1 | 20040128 | EP 2002-717548 | 20020305 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2002007961 | A | 20040420 | BR 2002-7961 | 20020305 |
| CN 1496256 | A | 20040512 | CN 2002-806571 | 20020305 |
| HU 200400203 | A2 | 20040830 | HU 2004-203 | 20020305 |
| JP 2004529904 | T | 20040930 | JP 2002-571044 | 20020305 |
| BG 108137 | A | 20050131 | BG 2003-108137 | 20030828 |
| ZA 2003007123 | A | 20041213 | ZA 2003-7123 | 20030911 |
| NO 2003004056 | A | 20031105 | NO 2003-4056 | 20030912 |
| US 2004214871 | A1 | 20041028 | US 2004-850072 | 20040520 |
| US 2005159461 | A1 | 20050721 | US 2004-9579 | 20041210 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 2001-316395P | P 20010831 |
| | | | US 2002-91061 | A3 20020305 |
| | | | WO 2002-US6746 | W 20020305 |

OTHER SOURCE(S): MARPAT 137:242152
 AB The invention discloses use of a combination of epothilone analogs and antitumor agents for the treatment and prevention of proliferative disorders.
 IT 219989-77-2 219989-79-4 219989-80-7
 219989-81-8

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses);
 (combination of epothilone analogs and antitumor agents for treatment of proliferative diseases)
 RN 219989-77-2 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-
 3,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-
 thiazolyl)ethenyl]-. (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 219989-79-4 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,
 7,11-dihydroxy-3,8,8,10,12-
 pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,
 (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 219989-80-7 CAPLUS
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-
 16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,
 (4S,7R,8S,9S,13S,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 219989-81-8 CAPLUS
 CN Oxacyclohexadec-13-ene-2,6-dione,
 4,8-dihydroxy-5,5,7,9,13,16-pentamethyl-16-
 [(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13S,16S)-
 (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:657954 CAPLUS
 DOCUMENT NUMBER: 137:195554
 TITLE: Treatment of refractory tumors using epothilone derivatives
 INVENTOR(S): Lee, Francis Y. F.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 38 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|---------------------------|
| WO 2002066038 | A1 | 20020829 | WO 2002-US4255 | 20020206 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2438610 | A1 | 20020829 | CA 2002-2438610 | 20020206 |
| EE 200300396 | A | 20031215 | EE 2003-396 | 20020206 |
| HU 200303175 | A2 | 20031229 | HU 2003-3175 | 20020206 |
| EP 1385529 | A1 | 20040204 | EP 2002-714885 | 20020206 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004522774 | T | 20040729 | JP 2002-565596 | 20020206 |
| BR 2002007487 | A | 20040810 | BR 2002-7487 | 20020206 |
| CN 1774253 | A | 20060517 | CN 2002-805251 | 20020206 |
| US 2002165258 | A1 | 20021107 | US 2002-72123 | 20020206 |
| US 6686380 | B2 | 20040203 | | |
| BG 108075 | A | 20050430 | BG 2003-108075 | 20030807 |
| ZA 2003006173 | A | 20041123 | ZA 2003-6173 | 20030808 |
| NO 2003003684 | A | 20031013 | NO 2003-3684 | 20030819 |
| PRIORITY APPLN. INFO.: | | | US 2001-269836P | P 20010220 |
| | | | | WO 2002-US4255 W 20020206 |

OTHER SOURCE(S): MARPAT 137:195554
 AB Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivs. selected from those represented by the formula. The subject epothilone derivs. are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncol.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 agents in that they are efficacious upon oral administration.
 IT 219989-77-2 219989-79-4 219989-80-7
 219989-81-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use): BIOL (Biological study); USES (Uses)
 (treatment of refractory tumors using epothilone derivs. in relation to mechanism and drug resistance)

RN 219989-77-2 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 219989-79-4 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3,8,8,10,12- pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 219989-80-7 CAPLUS
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13Z,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 219989-81-8 CAPLUS
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,16-pentamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13Z,16S)- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACESSION NUMBER: 1999:64791 CAPLUS
 DOCUMENT NUMBER: 130:139205
 TITLE: syntheses of epothilone derivatives and intermediates for use in treatment of hyperproliferative cellular disease
 INVENTOR(S): Vite, Gregory D.; Bortilleri, Robert M.; Kim, Soong-hoon; Johnson, James A.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIIXX2D
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-------------------|----------|
| WO 9902514 | A2 | 19990121 | WO 1998-US12550 | 19980616 |
| WO 9902514 | A3 | 20010510 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| US 6605599 | B1 | 20030812 | US 1998-84542 | 19980526 |
| CA 2296012 | A1 | 19990121 | CA 1998-2296012 | 19980616 |
| AU 9879720 | A | 19990208 | AU 1998-79720 | 19980616 |
| AU 731497 | B2 | 20010329 | | |
| EP 1019389 | A2 | 20000719 | EP 1998-930300 | 19980616 |
| EP 1019389 | B1 | 20051109 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| BR 9810555 | A | 20000815 | BR 1998-10555 | 19980616 |
| EE 200000013 | A | 20000815 | EE 2000-13 | 19980616 |
| EE 4566 | B1 | 20051215 | | |
| TR 200000065 | T2 | 20001121 | TR 2000-200000065 | 19980616 |
| NZ 501198 | A | 20010928 | NZ 1998-501198 | 19980616 |
| JP 2002512634 | T | 20020423 | JP 1999-508673 | 19980616 |
| HU 200103111 | A2 | 20020429 | HU 2001-3111 | 19980616 |
| RU 2213741 | C2 | 20031010 | RU 2000-102893 | 19980616 |
| EP 1493738 | A1 | 20050105 | EP 2004-21059 | 19980616 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| EP 1526133 | A1 | 20050427 | EP 2004-28580 | 19980616 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| EP 1531153 | A1 | 20050518 | EP 2004-28581 | 19980616 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| AT 309236 | T | 20051115 | AT 1998-930300 | 19980616 |
| IL 133613 | A | 20051120 | IL 1998-133613 | 19980616 |
| RO 120340 | B1 | 20051230 | RO 1999-1332 | 19980616 |

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ES 2251088 T3 20060416 ES 1998-930300 19980616
 TW 562802 B 20031121 TW 1998-87110722 19980702
 ZA 9805938 A 20000110 ZA 1998-5938 19980706
 MX 9911452 A 20000630 MX 1999-11452 19991209
 LT 4743 B 20001227 LT 1999-153 19991223
 NO 2000000076 A 20000107 NO 2000-76 20000107
 NO 322494 B1 20061016 BG 2000-104068 20000110
 BG 64952 B1 20061031 BG 2000-104068 20000110
 LV 12565 B 20010420 LV 2000-17 20000202
 HK 1026905 A1 20060331 HK 2000-106086 20000926
 US 2003220295 A1 20031127 US 2003-405886 20030403
 US 7125699 B2 20061024
 US 2006287371 A1 20061221 US 2006-512623 20060830
 PRIORITY APPLN. INFO.: US 1997-51951P P 19970708
 US 1997-67524P P 19971204
 US 1998-64542 A1 19980526
 EP 1998-930300 A3 19980616
 WO 1998-US12550 W 19980616
 US 2003-405886 A1 20030403

OTHER SOURCE(S): MARPAT 130:139205
 GI .




AB Syntheses of epothilone derivs. (I) (R = H, Me; A = CH₂, O, NH; X = H when bond double, α -epoxy when bond single) and intermediates for use in treatment of hyperproliferative cellular disease are described.

IT 219989-77-2 219989-79-4 219989-80-7
 ZI19989-81-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
 (syntheses of epothilone analogs and intermediates for use in treatment of hyperproliferative cellular disease)

RN 219989-77-2 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3,8,8,10,12-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]- (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



RN 219989-79-4 CAPLUS
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3,8,8,10,12-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

16 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 219989-80-7 CAPLUS
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-
 16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13Z,16S)-
 (4S,7R,8S,9S,13Z,16S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 219989-81-8 CAPLUS
 CN Oxacyclohexadec-13-ene-2,6-dione,
 4,8-dihydroxy-5,5,7,9,16-pentamethyl-16-

16 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 [(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13Z,16S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



Page 11

| | | |
|--|------------|---------|
| => log y | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 27.33 | 200.09 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -3.90 | -3.90 |

STN INTERNATIONAL LOGOFF AT 17:15:42 ON 20 FEB 2007